Jeremy Levin | |
|---|---|
 | |
| Born | 1954 (age 69–70) South Africa |
| Nationality | American |
| Alma mater | Oxford University, Cambridge University |
| Occupation(s) | Chairman and CEO, Ovid Therapeutics Inc |
| Spouse | Margery Feldberg (m. 1987) |
| Children | 2 |
Jeremy Levin (born 1954) is a South African-born businessman, medical doctor and research scientist. In 2018, Levin was named as one of the most influential figures in the biopharmaceutical industry. [1]
Jeremy Levin was born in South Africa, where his family had a farm, De Hoek Farm, in Piketberg, Western Cape. His father Archie (died 1977) was a political journalist. His mother, Leah Levin OBE, is Hon. Doctor of the University of Essex. [2] She served on the board of the United Nations Association, Anti-Slavery and International Alert, and was director of JUSTICE from 1982 to 1992. [3] Ms. Levin also served on Boards of Redress, Readers International, and the International Journal of Human Rights. [4] She is the author of UNESCO's "Human Rights: Questions and Answers," one the world's widely disseminated books on human rights. [5] He is the brother of David and sister Michal Levin. [6]
Following the Sharpeville massacre, his family left South Africa and moved to live in Salisbury, Rhodesia (now Harare, Zimbabwe).[ citation needed ] In 1965, his father was given a day to leave the country.[ citation needed ] The family arrived in Britain knowing nobody, settling in London. He attended Holland Park School. [7] Following graduating from high school, Levin went to Wadham College, University of Oxford, where he gained a First Class BA Honors degree in zoology, and a Master of Arts (MA) and doctorate (DPhil) in cell biology and chromatin structure from the Oxford University's Sir William Dunn School of Pathology. He subsequently received an MB, BChir degree (Bachelor of Medicine, Bachelor of Surgery) from the University of Cambridge.
Prior to his business experience Levin practised medicine, working at university hospitals including the Hammersmith Hospital in London, Groote Schuur in Cape Town, South Africa and Hôpitaux universitaires de Genève, Geneva, Switzerland.
In 1986, Levin came to America where he has worked in the biopharmaceutical industry in progressively senior positions. While living in Washington, D.C. Levin met Margery Feldberg (daughter of Stanley Feldberg, co-founder of TJX Companies). They married in September 1987 and have two daughters. [8] He has lived in New Milford since the 1980s, where he and his wife own De Hoek Farm, raising Black Angus cows. [9]
Levin is the chairman and CEO of Ovid Therapeutics Inc., a company dedicated to providing innovative medicines to children and adults with neurological disorders. [10] [11] Ovid's initial product development programs are focused on orphan and rare diseases of the brain, including Angelman syndrome and Fragile X syndrome.
Prior to joining Ovid, Levin served as president and CEO of Israel's Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), one of the world's largest pharmaceutical companies. [12] [13] Previously, he was a member of the executive committee of Bristol-Myers Squibb (NYSE:BMY), where he had global responsibilities for strategy, alliances and transactions. [14] In this role, he devised and led BMY's “String of Pearls” business development strategy. This strategy helped drive the transformation of BMY, particularly following the acquisition by Levin of Medarex Inc. in July 2009, which positioned BMY as a leader in immunooncology. [15] [16] [17] Prior to this, Levin was head of global business development and strategic alliances at Novartis (NYSE: NVS), and previously served as chairman and CEO of Cadus Pharmaceuticals, Inc. [18] [19]
Levin currently serves on the board of H. Lundbeck A/S and in 2019 was elected as the chairman of the Biotechnology Innovation Organization (BIO). [20] [21] [22]
Levin is a frequent speaker at biopharmaceutical conferences, where his focus is driving deeper and more direct relationships between companies and patients, ensuring innovation in the biopharmaceutical industry, expanding the role of mergers and acquisitions, globalising the biopharmaceutical industry, and propelling interface of the digital health and biopharmaceutical industries and leadership. [23] [24]
Levin is the recipient of a number of awards, including:
AstraZeneca plc (AZ) is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. It has been involved in developing the Oxford–AstraZeneca COVID-19 vaccine.
The Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb (BMS), is an American multinational pharmaceutical company. Headquartered in Princeton, New Jersey, BMS is one of the world's largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations. For fiscal 2022, it had a total revenue of $46.2 billion.
ZymoGenetics, Inc was one of the oldest biotechnology/pharmaceutical companies in the USA, based in Seattle, Washington. The company was involved in the development of therapeutic proteins. Located on Lake Union, the address of the ZymoGenetics headquarters was 1201 Eastlake Avenue East. It was closed in 2019 after its acquisition by Bristol Myers Squibb.
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
Biocon Limited is an Indian biopharmaceutical company based in Bangalore. It was founded by Kiran Mazumdar-Shaw in 1978. The company manufactures generic active pharmaceutical ingredients (APIs) that are sold in approximately 120 countries, including the United States and Europe. It also manufactures novel biologics as well as biosimilar insulins and antibodies, which are sold in India as branded formulations. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets.
Celgene Corporation is a pharmaceutical company that makes cancer and immunology drugs. Its major product is Revlimid (lenalidomide), which is used in the treatment of multiple myeloma, and also in certain anemias. The company is incorporated in Delaware, headquartered in Summit, New Jersey, and a subsidiary of Bristol Myers Squibb (BMS).
John Mendlein is a biotech executive who has held leadership positions in biotech companies in Boston, San Diego and Toronto.
Medarex was an American biopharmaceutical company based in Princeton, New Jersey, with manufacturing facilities in Bloomsbury and Annandale, New Jersey, and research facilities in Milpitas and Sunnyvale, California. In 2009, Medarex was purchased by Bristol Myers Squibb.
Amylin Pharmaceuticals, Inc. is a biopharmaceutical founded in 1987 that was based in San Diego, California. The company was engaged in the discovery, development, and commercialization of drug candidates for the treatment of diabetes, obesity, and other diseases. Amylin produced three drugs: Symlin, Byetta (exenatide) and Bydureon.
Kosan Biosciences, Inc., was a pharmaceutical company which dealt with cancer therapeutics medications. The company was working on advancing two new classes of anticancer agents through clinical development: heat shock protein 90 (Hsp90) inhibitors and epothilones.
Nivolumab, sold under the brand name Opdivo, is an anti-cancer medication used to treat a number of types of cancer. This includes melanoma, lung cancer, malignant pleural mesothelioma, renal cell carcinoma, Hodgkin lymphoma, head and neck cancer, urothelial carcinoma, colon cancer, esophageal squamous cell carcinoma, liver cancer, gastric cancer, and esophageal or gastroesophageal junction cancer. It is administered intravenously.
Lamberto Andreotti is an Italian businessman. He is currently executive chairman of the board of Bristol Myers Squibb.
BMS-906024 is a drug with a benzodiazepine structure, developed by Bristol-Myers Squibb and disclosed at the spring 2013 American Chemical Society meeting in New Orleans to treat breast, lung, colon cancers and leukemia. The drug works as a pan-Notch inhibitor. The structure is one of a set patented in 2012, and is being studied in clinical trials.
Endocyte is a biopharmaceutical company established in 1996 and headquartered in West Lafayette, Indiana, a resident of the Purdue Research Park. In 2011 the company completed successfully an initial public offering (IPO). As of 2013, the company had 93 employees. The original president and CEO, Ron Ellis, was succeeded by Mike Sherman, who held a CFO position at the company before this change in June 2016. In 2018 the company was acquired by Novartis.
Juno Therapeutics Inc was an American biopharmaceutical company founded in 2013 through a collaboration of the Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and pediatrics partner Seattle Children's Research Institute. The company was launched with an initial investment of $120 million, with a remit to develop a pipeline of cancer immunotherapy drugs. The company raised $300 million through private funding and a further $265 million through their IPO.
Editas Medicine, Inc.,, is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado.
IFM Therapeutics is a pharmaceutical company focused on developing biological treatments for autoimmune diseases.